提供学术论文选刊润色服务
医学
医学
Paper Review Records
全部论文审稿周期
10 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
69
天
How to Optimize Healthy Volunteer Screening and Enrolment in Clinical Trials: A Qualitative and Quantitative Approach to Evaluate Processes and Healthy Volunteers' Perceptions
作者Evelyn Krohmer; Manuela König; Cathrin J. Vogt; Marina Streckebein; Sybille Baumann; Max Blumenstock; Ruwen Böhm; Fabian Müller; Nadja Struß; Viktoria S. Wurmbach; Antje Blank
作者单位1. Internal Medicine IX, Department of Clinical Pharmacology and Pharmacoepidemiology Medical Faculty Heidelberg University/Heidelberg University Hospital Heidelberg Germany; 2. CRS hVIVO Mannheim Germany; 3. CRS Berlin Germany; 4. Institute of Medical Informatics Heidelberg University Heidelberg Germany; 5. Socratec Erfurt Germany; 6. Boehringer Ingelheim Pharma GmbH & Co. KG Biberach an der Riß Germany; 7. Institute of Experimental and Clinical Pharmacology and Toxicology Friedrich‐Alexander‐Universität Erlangen‐Nürnberg Erlangen Germany
70
天
Phase I Evaluation of Siltartoxatug, a First‐in‐Class Anti‐Tetanus Monoclonal Antibody: Safety, Pharmacokinetics and Pharmacodynamics in Healthy Australian and Chinese Populations
作者Xinyu Liu; Zhigang Liu; Xiaohu Kuang; Yueming Wang; Xiaoyi Liu; Jiyuan Ding; Xia Zhou; Xin Zhou; Qianyu Liang; Meizhuo Zhang; Hao Zhao; Qingqing Tan; Weihong Zheng; Huaxin Liao; Charlotte Lemech; Wanmei Wang
作者单位1. Zhuhai Trinomab Pharmaceutical Co., Ltd. Zhuhai China; 2. The Fifth Affiliated Hospital Sun Yat‐sen University Zhuhai China; 3. Present address: Cancer Center, The Tenth Affiliated Hospital Southern Medical University (Dongguan People's Hospital) Dongguan China; 4. Scientia Clinical Research Ltd. Sydney Australia
195
天
Exposure–Response Analysis of Enfortumab Vedotin Plus Pembrolizumab as First‐Line Therapy for Locally Advanced or Metastatic Urothelial Cancer
作者Vaishali L. Chudasama; Helen Kastrissios; Hossam Kadry; Daping Zhang; Salaheldin Hamed; Srinivasu Poondru; Souvik Bhattacharya; Russ Wada; Amit Garg; Yen Lin Chia
作者单位1. Pfizer Inc New York New York USA; 2. QuanTx Consulting Mountain View California USA; 3. Astellas Pharma Northbrook Illinois USA; 4. BeOne Medicines San Carlos California USA
103
天
Effects of Fomepizole on Acetaminophen Oxidative Metabolism: A Randomized, Crossover Study in Human Volunteers
作者Sidharth Anand; Nicholas A. Buckley; Paul Stathakis; Laura James; Larry Parker; Mitchell R. McGill; Angela L Chiew
作者单位1. Faculty of Medicine The University of New South Wales Sydney New South Wales Australia; 2. Faculty of Medicine and Health The University of Sydney Camperdown New South Wales Australia; 3. NSW Health Pathology, Prince of Wales Hospital Randwick New South Wales Australia; 4. Department of Pediatrics, College of Medicine University of Arkansas for Medical Sciences Little Rock Arkansas USA; 5. Acetaminophen Toxicity Diagnostics, LLC Little Rock Arkansas USA; 6. Department of Environmental Health Sciences, Fay W. Boozman College of Public Health University of Arkansas for Medical Sciences Little Rock Arkansas USA; 7. Department of Pharmacology and Toxicology, College of Medicine University of Arkansas for Medical Sciences Little Rock Arkansas USA; 8. Department of Clinical Toxicology Prince of Wales Hospital Randwick New South Wales Australia
117
天
Epcoritamab Step‐Up Dosing Regimen Selection and Optimization Using Repeated Time‐to‐Event Modeling for Cytokine Release Syndrome Risk Mitigation
作者Tommy Li; Andrew Tredennick; Daniel Polhamus; Matthew Putnins; Sihang Liu; Kinjal Sanghavi; Craig J. Thalhauser; Apurvasena Parikh; Behnam Noorani; Mohamed‐Eslam F. Mohamed; Chris Le Gallo; Brian Elliott; Manish Gupta; Steven Xu
作者单位1. Genmab Princeton New Jersey USA; 2. Metrum Research Group Boston Massachusetts USA; 3. AbbVie Inc. North Chicago Illinois USA
125
天
9
天
81
天
Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi‐Regional Clinical Trials and Future Pathways
作者Yosuke Kobayashi; Nobuko Matsushima; Noriyuki Takai; Daisuke Sato; Shinichiro Hoshino; Akihiro Ishiguro; Yasuo Iimura
作者单位1. Pharmaceuticals and Medical Devices Agency Tokyo Japan; 2. Johnson & Johnson J&J Innovative Medicine Tokyo Japan; 3. Drug Evaluation Committee Japan Pharmaceutical Manufacturers Association Tokyo Japan; 4. EPS Corporation Tokyo Japan; 5. Ministry of Health, Labour and Welfare Tokyo Japan; 6. Eli Lilly Japan K.K. Kobe Japan
100
天
Resolving CYP2D6 Structural Complexity with Long‐Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients
作者Usa Boonyuen; Sirinyatorn Talukam; Beatriz Aira C. Jacob; Wayu Matphong; Kamonwan Chamchoy; Onrapak Reamtong; Nuntana Meesiripan; Junya Yamagishi; Matthew Phanchana; Chayanoot Rattadilok
作者单位1. Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine Mahidol University Bangkok Thailand; 2. Princess Srisavangavadhana Faculty of Medicine Chulabhorn Royal Academy Bangkok Thailand; 3. National Cancer Institute Bangkok Thailand; 4. International Institute for Zoonosis Control Hokkaido University Hokkaido Japan
123
天
Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin–Angiotensin System Inhibitors
作者Katherine L. Crum; Muthiah Vaduganathan; Rishi J. Desai
作者单位1. Department of Epidemiology Harvard T.H. Chan School of Public Health Boston Massachusetts USA; 2. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts USA; 3. Division of Cardiovascular Medicine Brigham and Women's Hospital Boston Massachusetts USA
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿96.4 天
中位数77 天